Bill Snyder
-
“Supermeres” may carry clues to cancer, Alzheimer’s disease and COVID-19
Vanderbilt researchers have discovered a nanoparticle released from cells, called a “supermere,” which contains enzymes, proteins and RNA associated with multiple cancers, cardiovascular disease, Alzheimer’s disease and even COVID-19. Read MoreDec 10, 2021
-
Gene discoveries give new hope to people who stutter
New research shows the potential to identify therapeutic directions that could improve outcomes for people who stutter. Read MoreDec 2, 2021
-
‘Pre-conditioning’ restores immune tolerance
A treatment targeting T-cell metabolism could reinvigorate immune tolerance mechanisms to combat autoimmune disease and transplant rejection, Vanderbilt researchers discovered. Read MoreSep 16, 2021
-
Potential protection from atherosclerosis
Vanderbilt researchers have discovered a potential way to reduce atherosclerosis: blocking the modification of an HDL-associated enzyme by reactive molecules called isolevuglandins. Read MoreAug 19, 2021
-
For more precise drug treatments, ‘squeeze’ the genome: study finds
Large-scale studies will be required to identify the complexity of genetic variations that affect how patients respond to a given drug and whether they will have side effects, according to researchers at Vanderbilt University Medical Center. Read MoreJul 22, 2021
-
Nature’s “recycler” could reduce heart disease risk: study
Researchers at Vanderbilt University Medical Center have identified potential new targets for the prevention of atherosclerosis through the enhancement of autophagy, a natural process for recycling damaged cellular material. Read MoreJul 8, 2021
-
Study finds genetic risk factors for severe COVID-19 illness
A massive worldwide collaboration including researchers from Vanderbilt University Medical Center (VUMC) has identified several genetic factors associated with SARS-CoV-2 infection and severe COVID-19 illness. Read MoreJul 8, 2021
-
Combination antibody therapies should retain effectiveness against emerging COVID-19 variants: study
Five monoclonal antibody “cocktails,” including one developed at Vanderbilt University Medical Center (VUMC), are protective in animal studies against several variant strains of COVID-19, according to a report this week in the journal Nature. Read MoreJun 22, 2021
-
Therapeutic antibodies for hantavirus
Vanderbilt Vaccine Center researchers have isolated monoclonal antibodies against hantaviruses, an emerging source of human disease with pandemic potential. Read MoreMay 24, 2021
-
New clue to lung scarring
Vanderbilt neonatology team pinpoints signaling pathways involved in the progressive lung fibrosis that occurs in rare genetic diseases. Read MoreMay 20, 2021
-
VUMC to lead national study to treat severe COVID complications
The Vanderbilt Institute for Clinical and Translational Research (VICTR) has been awarded a major federal grant to lead a national trial of treatments targeting the Renin Angiotensin Aldosterone System (RAAS) in patients hospitalized with COVID-19. Read MoreMay 6, 2021
-
VUMC aids national effort to repurpose drugs for COVID-19
Vanderbilt University Medical Center (VUMC) has been named Data Coordinating Center (DCC) for a nationwide platform of studies aimed at “repurposing” existing drugs to treat mild to moderate symptoms of COVID-19. Read MoreApr 19, 2021
-
New insights into kidney development
Integrin-linked kinase, a central component of a complex that coordinates cell signaling involved in migration, proliferation and cell death, plays a role in kidney development and epithelial cell function. Read MoreApr 15, 2021
-
Personalized Structural Biology aids cancer treatment decisions
Cancer specialists at Vanderbilt University Medical Center, in partnership with biochemists and structural biologists across the Vanderbilt University campus, are taking “personalized” cancer therapy to a new level. Read MoreApr 8, 2021
-
Novel way to neutralize Rift Valley Fever Virus
The discovery of monoclonal antibodies that neutralize Rift Valley Fever Virus — an emerging infection with pandemic potential — lays the foundation for future therapeutic antibody development. Read MoreApr 1, 2021
-
Study shows new COVID target could improve vaccines
Despite an impressive vaccination effort that exceeds 2 million shots a day, rates of COVID-19 are again on the rise in several parts of the United States, as is the spread of highly transmissible variants of the virus. Read MoreApr 1, 2021
-
Physician-scientists Aliyu, Tindle elected to ASCI
Vanderbilt’s Muktar Aliyu, MBBS, MPH, DrPH, and Hilary Tindle, MD, MPH, will be inducted this year into the American Society for Clinical Investigation (ASCI), an elite honor society of physician-scientists from the upper ranks of academic medicine and industry. Read MoreMar 31, 2021
-
Study to assess allergic reactions to COVID vaccines
Vanderbilt University Medical Center is recruiting volunteers for a randomized controlled phase 2 clinical trial to help determine the prevalence of systemic allergic reactions (SARS) to the two-dose COVID-19 mRNA vaccines made by Pfizer-BioNTech and Moderna. Read MoreMar 18, 2021
-
Research Staff Awards honor those who help drive engines of discovery
Laboratory and administrative personnel at Vanderbilt University Medical Center were honored last week for research excellence during the 17th annual Research Staff Awards, held virtually this year because of the pandemic. Read MoreFeb 18, 2021
-
New clue to postural tachycardia
Insight into the pathophysiology of an enigmatic and debilitating disease suggests new treatment approaches. Read MoreFeb 4, 2021